Equity Profile

GH

Guardant Health, Inc.

Health CareHealth Care Services$21.0B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Guardant Health, Inc. is a healthcare company specializing in cancer detection and monitoring through advanced blood tests....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, and investors will be keen to see if Guardant can continue its trend of beating expectations.

N/A

Revenue Growth

As a healthcare services company, revenue growth is vital for sustaining operations and funding research and development for new tests.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GH Q2-2026 Earnings Preview

Context

Company Snapshot

Guardant Health, Inc. is a healthcare company specializing in cancer detection and monitoring through advanced blood tests. With a market cap of $21 billion, it plays a crucial role in the growing field of precision medicine, which aims to tailor treatments based on individual patient profiles.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+38.36%

Avg Stock Reaction

+1.55%

Last Quarter Recap

In the last quarter, Guardant Health reported an EPS of -$0.45, outperforming analyst expectations by nearly 37%. The stock saw a slight increase of 0.01% the following day, indicating a cautious market response.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, Wall Street appears cautiously optimistic about Guardant Health's upcoming earnings, especially given its strong track record of beating EPS estimates. However, the lack of specific guidance may lead to uncertainty among investors.

Bull Case

If Guardant continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the high implied volatility in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and will it continue the trend of beating estimates?

Given Guardant's history of positive EPS surprises, this figure will be critical for investor sentiment and stock performance.

What are the revenue growth projections for Guardant's liquid biopsy tests?

As the market for cancer detection evolves, understanding revenue growth will indicate the company's competitive position and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Guardant's ability to leverage its recent technological advancements in liquid biopsy, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

Guardant has consistently beaten EPS estimates, suggesting operational strength that may not be fully recognized.

The options market indicates a high implied move, reflecting expectations of significant volatility that could favor positive outcomes.

Historical trends show that the stock has reacted positively to earnings beats, which may not be fully accounted for in current sentiment.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious outlook and drive the stock higher.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus will be on whether Guardant can maintain its positive earnings trajectory and demonstrate growth in its key markets.

Bull Confirmed If

An EPS of -$0.30 or better would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS worse than -$0.50 would confirm the bear case, suggesting potential challenges in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±28.22%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±28.2% while GH has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.6%

Calls (119K)P/C Ratio: 0.19Puts (15K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Guardant beats expectations, history suggests a positive reaction, with an average move of +1.55% on such occasions, confirming investor confidence.

In-Line / Cautious

If results are in line but lack strong guidance, the stock may experience muted movement as investors reassess their outlook.

Miss

A miss could lead to a significant downturn, with historical data suggesting an average move of -4.64% following disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in liquid biopsy technology.
2Details on partnerships or collaborations that could enhance market reach.
3Insights into customer adoption rates for existing tests.
4Management's outlook on competitive pressures in the healthcare market.
5Any commentary on regulatory changes that could impact operations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Guardant Health, Inc. is a healthcare company specializing in cancer detection and monitoring through advanced blood tests....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, and investors will be keen to see if Guardant can continue its trend of beating expectations.

N/A

Revenue Growth

As a healthcare services company, revenue growth is vital for sustaining operations and funding research and development for new tests.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

GH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+38.36%

Avg Stock Reaction

+1.55%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Guardant continues its trend of beating EPS estimates, it could signal strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and will it continue the trend of beating estimates?

Given Guardant's history of positive EPS surprises, this figure will be critical for investor sentiment and stock performance.

What are the revenue growth projections for Guardant's liquid biopsy tests?

As the market for cancer detection evolves, understanding revenue growth will indicate the company's competitive position and future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Guardant's ability to leverage its recent technological advancements in liquid biopsy, which could lead to stronger-than-expected revenue growth.

Supporting Evidence

Guardant has consistently beaten EPS estimates, suggesting operational strength that may not be fully recognized.

The options market indicates a high implied move, reflecting expectations of significant volatility that could favor positive outcomes.

Historical trends show that the stock has reacted positively to earnings beats, which may not be fully accounted for in current sentiment.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious outlook and drive the stock higher.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus will be on whether Guardant can maintain its positive earnings trajectory and demonstrate growth in its key markets.

Bull Confirmed If

An EPS of -$0.30 or better would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS worse than -$0.50 would confirm the bear case, suggesting potential challenges in the business.

Pre-Earnings Positioning

Options Market

Implied Move

±28.22%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±28.2% while GH has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.6%

Calls (119K)P/C Ratio: 0.19Puts (15K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Guardant beats expectations, history suggests a positive reaction, with an average move of +1.55% on such occasions, confirming investor confidence.

In-Line / Cautious

If results are in line but lack strong guidance, the stock may experience muted movement as investors reassess their outlook.

Miss

A miss could lead to a significant downturn, with historical data suggesting an average move of -4.64% following disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in liquid biopsy technology.
2Details on partnerships or collaborations that could enhance market reach.
3Insights into customer adoption rates for existing tests.
4Management's outlook on competitive pressures in the healthcare market.
5Any commentary on regulatory changes that could impact operations.